Y Mabs Therapeutics Stock Investor Sentiment

YMAB Stock  USD 10.01  0.27  2.63%   
About 75% of Y MAbs' investor base is looking to short. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Y MAbs Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Y MAbs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over two months ago at simplywall.st         
Y-mAbs Therapeutics, Inc. Held Back By Insufficient Growth Even After Shares Climb 33
Simply Wall St News at Macroaxis
over three months ago at finance.yahoo.com         
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Specia...
Yahoo News
over three months ago at simplywall.st         
Institutional investors may overlook Y-mAbs Therapeutics, Inc.s recent US57m market cap drop as long...
Simply Wall St News at Macroaxis
over three months ago at globenewswire.com         
Y-mAbs to Participate in Upcoming Investor Conferences in September
Macroaxis News: globenewswire.com
over three months ago at news.google.com         
Disposition of 50000 shares by Lund-hansen Torben of Y MAbs at 15.37 subject to Rule 16b-3
Google News at Macroaxis
over three months ago at news.google.com         
Insider Selling Y-mAbs Therapeutics, Inc. COO Sells 5,000 Shares of Stock - MarketBeat
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Disposition of 5000 shares by Joris Wilms of Y MAbs at 14.69 subject to Rule 16b-3
Macroaxis News
over three months ago at www.macroaxis.com         
Disposition of 28629 shares by Bo Kruse of Y MAbs at 2.0 subject to Rule 16b-3
Macroaxis News
over three months ago at simplywall.st         
Y-mAbs Therapeutics Second Quarter 2024 Earnings EPS Misses Expectations
Simply Wall St News at Macroaxis
over three months ago at insidermonkey.com         
Y-mAbs Therapeutics, Inc. Q2 2024 Earnings Call Transcript
insidermonkey News
over three months ago at gurufocus.com         
Y-mAbs Therapeutics Inc Q2 2024 Earnings EPS Misses at -0. ...
Gurufocus Stories at Macroaxis
over three months ago at investorplace.com         
YMAB Stock Earnings Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q2 2024
sbwire news
over three months ago at zacks.com         
Y-mAbs Therapeutics, Inc. Reports Q2 Loss, Misses Revenue Estimates
zacks News
over three months ago at globenewswire.com         
Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
Macroaxis News: globenewswire.com
over three months ago at finance.yahoo.com         
Why Y-mAbs Therapeutics Stock Got Mashed on Monday
Yahoo News
Far too much social signal, news, headlines, and media speculation about Y MAbs that are available to investors today. That information is available publicly through YMAB media outlets and privately through word of mouth or via YMAB internal channels. However, regardless of the origin, that massive amount of YMAB data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Y MAbs news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Y MAbs relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Y MAbs' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Y MAbs alpha.

Y MAbs Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Insider Selling Y-mAbs Therapeutics, Inc. Insider Sells 65,000 Shares of Stock
09/18/2024
2
Disposition of 22831 shares by Thomas Gad of Y MAbs at 4.38 subject to Rule 16b-3
09/19/2024
3
Insider Trading
09/27/2024
4
Disposition of 722 shares by Ber Gerard of Y MAbs at 12.0 subject to Rule 16b-3
10/04/2024
5
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA in Japan
11/04/2024
6
What To Expect From Y-mAbs Therapeutics Inc Q3 2024 Earnings
11/07/2024
7
Paradigm Biocapital Advisors LP Bolsters Position in Y-mAbs Therapeutics Inc
11/15/2024
8
The Market Doesnt Like What It Sees From Y-mAbs Therapeutics, Inc.s Revenues Yet As Shares Tumble 26
11/19/2024
9
Y-mAbs Omburtamab Failure The Critical Turning Point And 19.65M Shareholder Settlement
11/22/2024
10
Y-mAbs to Participate at Citis 2024 Global Healthcare Conference
11/27/2024
11
Acquisition by Wg Biotech Aps of 30671 shares of Y MAbs at 5.8125 subject to Rule 16b-3
12/06/2024
12
We Think Y-mAbs Therapeutics Can Afford To Drive Business Growth
12/10/2024

Complementary Tools for YMAB Stock analysis

When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Global Correlations
Find global opportunities by holding instruments from different markets
CEOs Directory
Screen CEOs from public companies around the world
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments